Caryn Peterson Joins ASPEN Neuroscience Board of Directors

SAN DIEGO, June 22, 2021 — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced today that Caryn Peterson, executive vice president of Regulatory Affairs for Gossamer Bio, has joined the Aspen Board of Directors.

 “We welcome Caryn as an important addition to our board of directors,” said Faheem Hasnain, Aspen’s chairman of the board. “With more than 30 years of regulatory affairs and clinical development experience, Caryn will provide critical guidance as Aspen prepares to enter the clinic and move through the FDA approval process.” 

“The next stage of Aspen’s growth includes building out our internal team of world-class scientists, and our external Board to advise and guide us as we progress towards the clinic,” said Damien McDevitt, PhD, president and CEO of Aspen Neuroscience.  “Caryn is a strong addition to our board of directors, and we are excited to have her join as we advance a new potential treatment for Parkinson’s for patients with few options.”

Having served in a variety of leadership roles in the pharmaceutical and biotech fields, Caryn has focused on the development, integration, and implementation of global clinical and regulatory strategy across a broad range of therapeutic areas, including her current position as executive vice president, regulatory affairs for Gossamer Bio. Prior to joining Gossamer in 2018, Caryn was managing partner of Development & Strategic Consulting (“DSC”) Associates, LLC, vice president of regulatory affairs at Syndax Pharmaceuticals, Inc., vice president of regulatory affairs at FeRx Incorporated, and held managerial positions in both pharmaceutical development and regulatory affairs at Amylin Pharmaceuticals. Caryn began her career as a staff scientist at Hybritech Incorporated. She has coauthored several research publications and is a co-inventor on multiple patent applications.

“It is an honor to be joining Aspen’s board of directors at such a pivotal time in the company’s development,” said Peterson. “This company has the potential to be a transformational force in both regenerative medicine and in neurodegenerative diseases.  I look forward to working with the Aspen team to make a real difference in the lives of Parkinson’s patients and their families.”

Please note that we at Aspen Neuroscience do not make determinations on who would be eligible for participation in clinical trials, and we do not offer tours of our laboratory. At this time, our therapy has not yet been used in humans and clinical trials have not begun.